Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder Joint

Osteoarthritis, Shoulder Clinical Trial

Official title: A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (CINGAL®) to Provide Symptomatic Relief of Osteoarthritis of Shoulder Joint

Status Completed

Clinical Trial Summary

This Trial will obtain clinical data to support an expanded indication for a single injection of Cingal used for the symptomatic relief of osteoarthritis in the shoulder joint.

Clinical Trial Description

Single injection into the shoulder joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH). Participants to be followed to 6 Months post-injection. ;

Related Conditions & MeSH terms

• Osteoarthritis
• Osteoarthritis, Shoulder

• NCT number: NCT04640961
• Study type: Interventional
• Source: Anika Therapeutics, Inc.
• Status: Completed
• Phase: N/A
• Start date: January 16, 2021
• Completion date: September 10, 2021